Allumeros

BioScience LLC

Our Focus

Three Initial Indications in a $20 Billion Opportunity

Difficult to Treat Indications with Poor Outcomes

Glioblastoma

  • 24,000 new cases of brain cancer diagnosed in US every year
  • 50% are glioblastoma’s (GBM)
  • 5 year survival rate is than 10%

Pancreatic Cancer

  • 55,000 cases per year (USA)
  • 44,000 deaths per year
  • 5 year survival rate is than 10%

Cardiac Ablation (Afib)

  • 7 Million cases of AFib in the USA.
  • Incidence is expected to double in the next 10 years

 

In each cases the current standard of care has not significantly “moved the needle” on outcomes. PNT offers a new and real opportunity to change this landscape for good.